Table 3.

Site-specific risk of MCC following other first primary cancers in the SEER Program (1986-2002)

Site of first cancerNo. of first cancersAll subsequent MCC
MCC occurring after 1 year*
No.SIR (95% CI)Median latency (y)No.SIR (95% CI)
First cancers, all2,048,7392211.36 (1.19-1.55)§41971.40 (1.21-1.61)§
Solid tumors, all1,826,2621841.20 (1.04-1.39)§41641.24 (1.05-1.44)§
Salivary gland5,24112.67 (0.03-14.84)5.813.17 (0.04-17.62)
Stomach39,1300[1.41]0[1.06]
Small intestine5,9460[0.34]0[0.29]
Colon161,356181.07 (0.64-1.70)4.2181.24 (0.74-1.96)
Rectum66,48840.65 (0.18-1.67)8.740.76 (0.20-1.94)
Other biliary**6,1180[0.20]0[0.14]
Lung254,29260.88 (0.32-1.92)1.530.63 (0.13-1.85)
Skin, malignant melanoma70,604163.05 (1.74-4.95)§6.8143.04 (1.66-5.09)§
Female breast321,190261.29 (0.84-1.89)5.5251.39 (0.90-2.05)
Female genital tract132,117101.56 (0.75-2.87)5.7101.77 (0.85-3.25)
Male genital tract††356,916711.13 (0.88-1.42)3.4581.04 (0.79-1.34)
Bladder84,622120.96 (0.50-1.68)4.9121.10 (0.57-1.92)
Kidney40,90562.17 (0.79-4.73)362.25 (0.82-4.89)
Brain29,3870[0.21]0[0.12]
Lymphohematopoietic, all173,994343.84 (2.66-5.37)§4304.11 (2.78-5.87)§
NHL81,743163.37 (1.93-5.47)§4.1133.28 (1.74-5.60)§
Multiple myeloma23,94943.70 (1.01-9.47)§3.444.91 (1.32-12.57)§
CLL17,315146.89 (3.77-11.57)§4.1137.43 (3.95-12.71)§
  • NOTE: Cancer sites presented in the table are those for which two or more subsequent cancers were observed after MCC (with the exception of multiple myeloma; i.e., replicated sites presented in Table 2). Squamous and basal cell carcinomas of the skin are not reportable to the SEER Program, except for genital sites, and thus, are not included in the analyses. For sites with zero observed cases, the expected number of cases is denoted in brackets [n].

  • * Risk excludes all cancers occurring within 1 year of a primary MCC diagnosis.

  • Risk excludes nine MCC occurring within 1 month of another first primary cancer diagnosis [lung (n = 3), prostate (n = 2), melanoma (n = 2), NHL (n = 1), and larynx (n = 1)].

  • Median time from diagnosis of first cancer to diagnosis of MCC.

  • § P < 0.05.

  • Excludes lymphohematopoietic malignancies (n = 34) and tumors classified as miscellaneous (n = 3).

  • Numbers include rectum and rectosigmoid junction.

  • ** Includes all biliary sites other than liver and gallbladder.

  • †† Includes the development of MCC as a second cancer in 70 men with prostate cancer and one with testis cancer.